<DOC>
	<DOCNO>NCT00882557</DOCNO>
	<brief_summary>The purpose study determine whether daptomycin high dose give last 30 minute dialysis session equal low dose daptomycin give dialysis session .</brief_summary>
	<brief_title>Study Evaluate Daptomycin Given During Dialysis After Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<criteria>Written inform consent prior studyrelated procedure part normal medical care ; Male female ≥ 18 year age ; If female childbearing potential ; willing practice reliable birth control measure study treatment least 28 day study completion , lactate pregnant , documented negative pregnancy test result within 24 hour prior study medication administration ; Endstage renal disease stable ( least 2 week ) hemodialysis regimen , three time weekly use highflux membrane ; Functioning hemodialysis access ( example , graft fistula ) ; Considered appropriate health study entry Investigator ( example , acute , debilitate medical problem ) appropriate candidate completing study treatment ; If take concomitant medication , subject must relatively stable dose least two week prior study drug administration . Received investigational drug ( include experimental biologic agent ) within 30 day study drug administration ; Has receive dose daptomycin within 7 day prior study drug administration ; Known allergic intolerant daptomycin ; Evidence active ongoing infection ; Known human immunodeficiency virus ( HIV ) infection CD4 count ≤ 200 cells/mm3 ; Active illicit drug use alcohol abuse ; Myocardial infarction within last 6 month ; Subject history muscular disease ( example , polymyositis , muscular dystrophy ) ; Subject history neurological disease ( example , Guillain Barré , multiple sclerosis ) , except stroke &gt; 6 month prior study entry ; Intramuscular injection within 7 day study drug administration ; Body mass index ( BMI ) ≤ 18.5 ≥ 40 kg/m2 ( BMI = weight [ kg ] /height [ m2 ] ) ; WBC ≥ 12 , 000 cells/mm3 ≤ 2500 cells/ mm3 ; Neutropenic subject absolute neutrophil count ≤ 500 cells/mm3 ; Baseline CPK value ≥ 3X ULN ( upper limit normal ) ; Alanine aminotransferase ( ALT ) &gt; 5XULN ; Aspartate aminotransferase ( AST ) &gt; 5XULN ; Hemoglobin ≤ 9 gm/dL ; Is consider unlikely comply study procedure return schedule posttreatment evaluation ; History rhabdomyolysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>End-stage renal disease</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>chronic renal failure</keyword>
</DOC>